Is visceral adipose tissue area an independent risk factor for hepatic steatosis?
Our results suggest that visceral abdominal adiposity is correlated with hepatic steatosis in healthy living liver donors.
Pexelizumab administration inhibits complement-dependent hemolytic activity and is associated with a reduction in postoperative chest tube drainage in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Further, clinical studies are needed to assess the value of complement attenuation in this setting.